Blog

Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia

Sep 1 • 5 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible note financing bearing interest at 15% per annum with a term of 12 months with Cantheon Capital for aggregate…

PanGenomic Health Inc Signs a Non-binding Letter of Intent for the Acquisition of Mindleap Health Inc.

Sep 1 • 4 min read

PanGenomic Health Inc,. (CSE: NARA), is pleased to announce that the Company has signed an arm’s length non-binding Letter of Intent with Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: 0NFA), to acquire all of the issued and outstanding shares of Mydecine’s wholly-owned subsidiary, Mindleap Health Inc. With over 40,000 organic downloads,…

Optimi Health Provides Progress Report On Year Of Commercialization

Sep 1 • 4 min read

Optimi Health Corp.(CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets, is pleased to provide an operational update on the progress of its planned year of…

Filament Health and ATMA Journey Centers Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial

Sep 1 • 3 min read

Filament Health Corp (OTCQB: FLHLF | NEO: FH) (FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and ATMA Journey Centers, a company focused on delivering effective and innovative experiences that leverage the potential of psychedelic medicine, today announced the recent dosing of 14 healthy subjects with Filament’s natural psilocybin drug candidate in a Health…

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Aug 31 • 4 min read

Bright Minds Biosciences (Nasdaq: DRUG | CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that it has dosed the first patient in a Phase I trial for its lead product, BMB-101, for the treatment of Dravet Syndrome and other medical indications….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538